- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
New Study Shows Complications Rare in Test-tube Fertility Procedures
The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.
The Associated Press reported that a new American 12-year study shows that complications are rare for women undergoing test-tube fertility procedures. Most frequently problems happen when drugs are used to stimulate ovaries, but even then fatalities don’t usually arise.
As quoted in the market news:
Over-stimulated ovaries occurred in 154 out of every 10,000 pregnancy attempts; rates of other complications were less than 10 per 10,000 attempts. There were 58 deaths reported during the 2000-11 study. The study lacks information on their causes, and with more than 1 million pregnancy attempts involved, the results are reassuring, said Dr. Jennifer Kawwass, an Emory University assistant professor and the lead author.
The study is the first large-scale effort to quantify risks for U.S. patients undergoing these treatments, Kawwass said. Results were published in Tuesday’s Journal of the American Medical Association.
Click here to read the full report from The Associated Press.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.